Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.

Djebbari F, Panitsas F, Eyre TA, Prodger C, Davies F, Burton K, Khera A, Vallance G, Moore S, Kothari J, Peniket A, Ramasamy K.

Haematologica. 2020 Jan 9. pii: haematol.2019.240762. doi: 10.3324/haematol.2019.240762. [Epub ahead of print] No abstract available.

2.

Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.

Djebbari F, Hubenov H, Neelakantan P, Wolf J, Offer M, Khera A, Louka E, Vallance G, Kothari J, Moore S, Ramasamy K.

Br J Haematol. 2020 Feb;188(4):e57-e60. doi: 10.1111/bjh.16324. Epub 2019 Dec 2. No abstract available.

PMID:
31792927
3.

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.

Sharpley FA, Djebbari F, Fourali S, Kothari J, Lynes JA, McLain-Smith S, Ramasamy K.

Leuk Lymphoma. 2019 Nov 27:1-5. doi: 10.1080/10428194.2019.1683737. [Epub ahead of print] No abstract available.

PMID:
31771382
4.

A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.

Eyre TA, Djebbari F, Kirkwood AA, Collins GP.

Haematologica. 2019 Sep 5. pii: haematol.2019.229948. doi: 10.3324/haematol.2019.229948. [Epub ahead of print]

5.

Resource implications of bortezomib therapy in a large UK cohort: An evaluation study.

Djebbari F, Tatarczuch M, Panitsas F, Vallance G, Sultanova M, Kothari J, Ramasamy K, Peniket A.

J Oncol Pharm Pract. 2019 Dec;25(8):1995-1998. doi: 10.1177/1078155219866500. Epub 2019 Aug 7.

PMID:
31390961
6.

Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.

Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora SM, Hatton CSR, Collins GP, Eyre TA.

Br J Haematol. 2019 Sep;186(6):e191-e195. doi: 10.1111/bjh.16071. Epub 2019 Jun 20. No abstract available.

PMID:
31222716
7.

Long term outcomes in monoclonal gammopathy of renal significance.

Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, Rabin N, Kothari J, Alchi B, Haynes R, Winearls C, Roberts I, Ramasamy K.

Br J Haematol. 2019 Sep;186(5):706-716. doi: 10.1111/bjh.15987. Epub 2019 May 29.

PMID:
31141168
8.

Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age.

Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR.

J Intern Med. 2019 Jun;285(6):681-692. doi: 10.1111/joim.12889. Epub 2019 Apr 11.

PMID:
30811713
9.

Clinical outcomes of bortezomib-based therapy in myeloma.

Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K.

PLoS One. 2018 Dec 12;13(12):e0208920. doi: 10.1371/journal.pone.0208920. eCollection 2018.

10.

A systematic review of non-standard dosing of oral anticancer therapies.

Djebbari F, Stoner N, Lavender VT.

BMC Cancer. 2018 Nov 22;18(1):1154. doi: 10.1186/s12885-018-5066-2.

11.

Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol.

Djebbari F, Stoner N, Lavender V.

Syst Rev. 2017 Dec 6;6(1):244. doi: 10.1186/s13643-017-0636-y.

12.

Treat or palliate: outcomes of very elderly myeloma patients.

Panitsas F, Kothari J, Vallance G, Djebbari F, Ferguson L, Sultanova M, Ramasamy K.

Haematologica. 2018 Jan;103(1):e32-e34. doi: 10.3324/haematol.2017.173617. Epub 2017 Oct 12. No abstract available.

Supplemental Content

Loading ...
Support Center